Mcl-1 downregulation by YM155 contributes to its synergistic anti-tumor activities with ABT-263.
about
YM155 Down-Regulates Survivin and Induces P53 Up-Regulated Modulator of Apoptosis (PUMA)-Dependent in Oral Squamous Cell Carcinoma Cells.Survivin, a molecular target for therapeutic interventions in squamous cell carcinoma.Pan-Bcl-2 inhibitor, GX15-070 (obatoclax), decreases human T regulatory lymphocytes while preserving effector T lymphocytes: a rationale for its use in combination immunotherapyYM155 induces EGFR suppression in pancreatic cancer cells.Cellular inhibitor of apoptosis protein 1 (cIAP1) stability contributes to YM155 resistance in human gastric cancer cells.Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1.YM155 potently kills acute lymphoblastic leukemia cells through activation of the DNA damage pathwayYM155 potently triggers cell death in breast cancer cells through an autophagy-NF-kB networkAML sensitivity to YM155 is modulated through AKT and Mcl-1.YM-155 potentiates the effect of ABT-737 in malignant human glioma cells via survivin and Mcl-1 downregulation in an EGFR-dependent context.Dioxonaphthoimidazoliums AB1 and YM155 disrupt phosphorylation of p50 in the NF-κB pathwaySurvivin inhibitor YM-155 sensitizes tumor necrosis factor- related apoptosis-inducing ligand-resistant glioma cells to apoptosis through Mcl-1 downregulation and by engaging the mitochondrial death pathwayApigenin sensitizes colon cancer cells to antitumor activity of ABT-263.Inhibitor of Apoptosis Proteins (IAPs) are commonly dysregulated in GIST and can be pharmacologically targeted to enhance the pro-apoptotic activity of imatinibRapamycin enhances the anti-angiogenesis and anti-proliferation ability of YM155 in oral squamous cell carcinoma.YM155 enhances ABT-737-mediated apoptosis through Mcl-1 downregulation in Mcl-1-overexpressed cancer cells.Effects of YM155 on survivin levels and viability in neuroblastoma cells with acquired drug resistance.Small Molecule Survivin Inhibitor YM155 Displays Potent Activity Against Human Osteosarcoma Cells.Putative tumor suppression function of SIRT6 in endometrial cancer.YM155 induces apoptosis through downregulation of specificity protein 1 and myeloid cell leukemia-1 in human oral cancer cell lines.MLN2238 synergizes BH3 mimetic ABT-263 in castration-resistant prostate cancer cells by induction of NOXA.The "survivin suppressants" NSC 80467 and YM155 induce a DNA damage response.YM155 sensitizes TRAIL-induced apoptosis through cathepsin S-dependent down-regulation of Mcl-1 and NF-κB-mediated down-regulation of c-FLIP expression in human renal carcinoma Caki cellsSepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance.Drug-perturbation-based stratification of blood cancer.Survivin inhibitor YM155 induces mitochondrial dysfunction, autophagy, DNA damage and apoptosis in Bcl-xL silenced glioma cell lines.Targeting the proliferative and chemoresistant compartment in chronic lymphocytic leukemia by inhibiting survivin protein.Survivin as a novel target protein for reducing the proliferation of cancer cells.Adaptation to chronic exposure to sepantronium bromide (YM155), a prototypical survivin suppressant is due to persistent DNA damage-response in breast cancer cells
P2860
Q33626354-E6664A0C-FF23-45C8-836E-2F36168F58FAQ33634679-453CA07C-953B-435A-B68B-713F5A84A2F7Q34004454-15C3662C-A2E4-44A9-BD6E-B2319C808ADEQ34313903-3B7F5B53-CE8B-4CB5-9EC6-9E8453EF242EQ34460429-FA3FF7B0-57DD-48CA-A6B5-AF7568B14873Q34786411-4C10A84C-65BC-4769-A6E3-1A02C2878E1BQ35534316-9EFB3586-AD3D-4161-A512-6613ED2A2B94Q35955360-97072296-B3B1-498F-85BC-8D42B69A7051Q35983805-48050729-4030-4AD7-A737-88E61340AA97Q36681060-F27BD4F8-DD16-48AC-A0D6-6E2EBC79F897Q36998326-7227B950-77F8-4D58-8B4C-C4321CE6AB2EQ37027010-15D12D57-4076-4CE3-B412-67ED8B97949BQ37410515-2CC975CE-B281-44D8-9320-CF845C6DB125Q37520240-C6A69DA8-9816-41A3-922A-B618552BE53FQ38700218-07F693C7-EE51-4607-8D7A-BFEDC749C26BQ38719564-3ACEF95E-C7E2-40E5-B241-E105A7896C4AQ38741378-5421B78B-737E-42CB-B0C5-0B8A8134C89BQ38750224-6F5929FA-223E-4B11-8942-AD97710DA053Q38852078-518DE091-68CB-459B-B9C0-6ADF2FE5255DQ38932250-8545C420-BC1C-4A4E-B42D-4EFF3EF91E1CQ38975047-1339B918-8D6D-4333-B090-8EF3F27D451CQ39360397-63AA4480-BC28-4DE0-8214-DF772050A441Q42029819-EEF4002C-C028-4645-8F27-3D2EA07DF58CQ42391580-068F3DC9-4A55-4560-B56C-3DFAF1D675B4Q47331796-569C2CF8-60DE-46ED-9B95-78F3061A09E0Q48445482-23EA4478-6A6C-4F56-BD74-4BB8DB1319ABQ51749083-F6711F32-4140-490C-A5A8-6207ADF749F8Q55006767-CC29E4B9-F9A4-4C5A-B0CC-2CC9641E25CFQ57493675-A83E2375-5C6C-4E60-8B7C-C0E9E7FCE06B
P2860
Mcl-1 downregulation by YM155 contributes to its synergistic anti-tumor activities with ABT-263.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Mcl-1 downregulation by YM155 ...... tumor activities with ABT-263.
@en
Mcl-1 downregulation by YM155 ...... tumor activities with ABT-263.
@nl
type
label
Mcl-1 downregulation by YM155 ...... tumor activities with ABT-263.
@en
Mcl-1 downregulation by YM155 ...... tumor activities with ABT-263.
@nl
prefLabel
Mcl-1 downregulation by YM155 ...... tumor activities with ABT-263.
@en
Mcl-1 downregulation by YM155 ...... tumor activities with ABT-263.
@nl
P2093
P1476
Mcl-1 downregulation by YM155 ...... tumor activities with ABT-263.
@en
P2093
Chunrong Yu
Haikuo Tang
Huanjie Shao
Jinsong Hou
P304
P356
10.1016/J.BCP.2011.07.064
P407
P577
2011-07-20T00:00:00Z